Murtola TJ, Vihervuori VJ, Lahtela J, Talala K, Taari K, Tammela TL, Auvinen A. Fasting blood glucose, glycemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Br J Cancer. 2018 May;118(9):1248-1254
Summary: Diabetic men have lowered overall risk of prostate cancer (PCa), but the role of hyperglycemia is unclear. In this cohort study we estimated PCa risk among men with diabetic fasting blood glucose level. Based on the average yearly level men were categorized as normoglycemic, prediabetic or diabetic. Compared to normoglycemic men, men with diabetic blood glucose level had increased risk of PCa. The risk increase was observed for all tumor grades, and persisted for a decade afterwards. Antidiabetic drug use removed the risk association.
Booth N, Rissanen P, Tammela TLJ, Taari K, Talala K, Auvinen A. Register-based healthcare cost estimates during the first 20 years of the Finnish Randomised study of Screening for Prostate Cancer. Eur J Cancer. 2018 Apr;93:108-118.
Summary: We estimate differences in register-based costs of publicly-funded healthcare in each arm of the Finnish Randomised study of Screening for Prostate Cancer (FinRSPC) after 20 years. For all men diagnosed with PCa during the 20-year observation period, PCa-related costs appeared to be less than 10% lower in the screening arm (SA) on average: 14,200 euros in the SA versus 15,300 euros in the control arm (CA). All-cause healthcare costs for these men were also lower in the SA on average, but differences were smaller than for PCa-related costs alone, and no longer statistically significant. For men dying from PCa, although the difference was not statistically significant, all-cause healthcare costs were around 10% higher on average: 65,100 euros in the SA versus 60,000 euros in the CA. Despite long-term follow-up of the FinRSPC cohort, the 20-year period is too short to provide definitive information about screening’s impact on healthcare costs.
Murtola TJ, Kasurinen TVJ, Talala K, Taari K, Tammela TLJ, Auvinen A. Serum cholesterol and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Accepted Prostate Cancer and Prostatic Diseases May 2018.
Summary: We examined PCa risk by lipid parameters in a population nested within the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). Cholesterol measurements were available for 17,696 men over 17-year median follow-up. Higher total cholesterol (TC) and LDL levels were associated with increased risk of Gleason 8-10 PCa. Overall PCa risk was elevated in men with higher TC and HDL with 3 years’ time lag. However, inverse risk association was seen with 20 years’ lag time for TC.